Please join PRA Health Sciences' Dr. Hazel Gorham as she talks with PharmaVoice about what a biobetter is, how biobetters compare to biosimilars, what the regulatory issues are, and bringing a biobetter to market.
Biosimilars Fact Sheet
Biosimilar drug development is unique and complex. At PRA, our cross-functional team of experts guide you through the many nuances of the biosimilar…
Biosimilars Newsletter Volume 4, October 2014
Welcome to the fourth edition of Biosimilars Newsletter, a quarterly publication dedicated to keeping you updated on current biosimilars news,…
Our collaborative, cross-functional team develops tailored, cost-effective services to meet the unique needs of biosimilars clinical development.